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Ethical Perspectives Regarding Antidepressant Drug Therapy During Pregnancy
Abstract
A literature review was conducted to evaluate and understand the effects of antidepressant medication
during pregnancy and the ethical issues surrounding the topic. Through the discussion of three articles,
the review weighed the effects of antidepressants on maternal and child health. Antidepressant
medication during pregnancy poses relative risks to cause fetal complications and defects, though the
risk remains very small. However, untreated depression may significantly impact the childbearing family,
including premature births, low birth weights, miscarriages, and suicide. Clinicians often have
misconceptions of the risks of untreated depression during pregnancy and could benefit from an
increased understanding of the current literature when making treatment decisions. Nevertheless, an
individual’s history, symptomatology, and an understanding of medications known to be harmful to the
fetus should guide the choice of treatment. Further research may help solidify understanding among
clinicians and the public and ultimately lead to improved health outcomes for both mother and child.
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Abstract
A literature review was conducted to evaluate and understand the effects of antidepressant medication
during pregnancy and the ethical issues surrounding the topic. Through the discussion of three articles, the
review weighed the effects of antidepressants on maternal and child health. Antidepressant medication during pregnancy poses relative risks to cause fetal complications and defects, though the risk remains very small.
However, untreated depression may significantly impact the childbearing family, including premature births,
low birth weights, miscarriages, and suicide. Clinicians often have misconceptions of the risks of untreated
depression during pregnancy and could benefit from an increased understanding of the current literature when
making treatment decisions. Nevertheless, an individual’s history, symptomatology, and an understanding of
medications known to be harmful to the fetus should guide the choice of treatment. Further research may help
solidify understanding among clinicians and the public and ultimately lead to improved health outcomes for
both mother and child.
Ethical Perspectives Regarding Antidepressant Drug
Therapy During Pregnancy
Depression affects one quarter of women during pregnancy (Cohen et al., 2006). Clinical trials
have demonstrated that medication and psychotherapy
are effective as stand-alone forms of treatment for
depression, yet a combination of the two treatment
options provides the most sustained response. But
how does pharmacological treatment impact the fetus?
Furthermore, what are the impacts of not treating the
pregnant woman? These are just a few of the questions that this paper will explore while examining the
ethical issues surrounding the use of antidepressant
drug therapy during pregnancy.
Antidepressant Medications During Pregnancy
Care must be taken when prescribing any
medication during pregnancy and an evaluation of the
risks and benefits to both the mother and fetus must
be considered. When life-threatening situations arise
and require immediate intervention during pregnancy,
it is common for “emergency” medications to be used.
However, with conditions that pose less of an immediate threat to life, such as depression, medications are
prescribed with greater hesitation (Payne &MeltzerBrody, 2009). The body of literature suggests that
common medications used to treat depression contribute to an increased risk including fetal heart defects,
limb malformation, and persistent pulmonary hypertension of the newborn (Malm, Artama, Gissler, &
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Ritvanen, 2011). Conversely, recent research indicates
that the likelihood of birth defects after prenatal exposure to certain psychiatric medications are not as great
as earlier studies had estimated (“Prescribing During
Pregnancy,” 2008).
An Ethical Issue
The ethical question is whether or not to take
antidepressant medications during pregnancy. Research indicates that antidepressants pose an increased
risk to the fetus. The research reviewed also indicates
that untreated depression during pregnancy increases
the rates of preterm births and substance abuse, both
of which pose an increased risk to the fetus and the
mother. Thus, one must evaluate the risks and benefits
in attempting to resolve the ethical situation.
The Effects on Maternal and Child Health
The article “Prescribing During Pregnancy”
(2008) from the Harvard Medical School’s Harvard
Mental Health Letter states that all psychiatric drugs
cross the placenta and reach the developing fetus, and
some increase the risk of certain congenital malformations. Furthermore, Cohen et al. (2006) found that
of 201 women with a history of Major Depressive
Disorder (MDD), 68% of those who stopped taking
antidepressants after becoming pregnant suffered a
relapse of depression, compared to a 26% incidence of
relapse in those who continued taking their antidepressants. Antenatal depression has been associated with
low maternal weight gain, increased rates of preterm
birth (Li, Liu, & Odouli, 2009), increased ambivalence
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about the pregnancy and overall worsened health (Orr,
Blazer, James, & Reiter, 2007). Additionally, prenatal
exposure to maternal stress has demonstrated consequences for the development of infant temperament
(Davis et al., 2005).

other known causes of PPHN including asthma, diabetes, and obesity. These factors were not part of the
exclusionary criteria for analysis in the study and thus
it is difficult to determine if it was the medication or
these other medical conditions that affected the data.
Prenatal drug exposure and an untreated psychiatric
Literature Review
disorder both present risks
This article reviews the risks of both prenatal
Antidepressant Use During Pregnancy:
psychotropic drug exposure and untreated psychiatric
Current Controversies and Treatment Strategies
disorder, though the primary focus of this publication
In this article, Payne and Meltzer-Brody (2009) was antidepressants and specifically SSRIs. An antideexamined the risks and benefits of antidepressant use
pressant that should not be used during pregnancy is
during pregnancy. Initially addressed is the “common paroxetine because it might increase the risk of several
misconception” that MDD is “different from, and not
types of rare congenital heart defects if used during the
as serious as, medical illness.” This often results in in- first trimester. Furthermore, when used during the last
appropriate discontinuation of antidepressants during
trimester of pregnancy, SSRIs as a class of medicapregnancy. Payne et al (2009) asserted that continutions that demonstrate temporary problems in as many
ation of medication should revolve around symptomas 25% of newborns, with common symptoms of
atology, where patients with mild MDD might discon- tremors, restlessness, mild respiratory problems, and
tinue therapy and more severe MDD may benefit from weak crying. “Prescribing During Pregnancy” (author,
continued therapy due to known risks of untreated
2008) reveals that “in most cases, these symptoms disdepression.
appear in the first few days after birth, although some
infants are admitted to the neonatal intensive care unit
Next, the authors discussed how the literaas a precaution.”
ture offers limited evidence to guide clinical practice
regarding antidepressant therapy in the pregnant
Putting Theory into Practice
woman and the inability to randomly assign depressed
pregnant women in clinical trials and the resultant
unknowns from limited data. They also referred to the Recommended Changes in Practice
limited helpfulness of the FDA Pregnancy Categories,
Based on the current research regarding antiincluding that “1) the FDA categories do not address
depressant use during pregnancy, [as future clinicians,
it is important to think of developing evidence based
dosing; 2) lack of consideration of time of exposure
to the medication; and 3) excessive reliance on animal guidelines that address the needs of this vulnerable
population] {my initial goal as a nurse would be to
data and lack of human data” (Payne and Meltzerwork to create evidence-based guideline.}guidelines.
Brody, 2009). The authors concluded that the safety
By creating guidelines for the use of antidepressants
of antidepressant use during pregnancy appears to
be reassuring, however state that two topics remain
during pregnancy, clinicians may provide increasingly
consistent information and care to pregnant women.
unclear: neonatal withdrawal syndrome and primary
Though additional research will solidify treatment
pulmonary hypertension of the newborn (PPHN).
approaches based on looming questions, the literaSSRI during pregnancy and risk of persistent pulture does offer a start to creating guidelines. First,
monary hypertension in the newborn
medications that are known to cause fetal harm should
Kieler et al. (2012) showed that exposure to
not be used. Second, an establishment of treatment
SSRI late in pregnancy was associated with an incriteria based on the severity of the symptoms should
creased risk of PPHN. Specifically, they concluded
guide usage. Third, the guidelines should include inthat the risk was double that of the general populaformation about the risks of abruptly stopping medication. This translates to 3 babies in every 1000 born
tion and the increased risk of usage of medication late
having PPHN versus 1 in every 1000 in the general
in pregnancy. A nurse may immediately implement all
population. It should be noted that although this is an of these into practice to educate, support and inform
increased risk relative to the general population, the
patients, leading to improved levels of care. Furtheroverall risk is relatively low. Furthermore, there are
more, attempts to increase awareness of clinicians by
https://repository.upenn.edu/josnr/vol6/iss1/1
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hosting educational meetings and journal clubs may
ensure that care reflects the current literature. Challenging the misconception that MDD during pregnancy is relatively benign to the fetus and woman serves
as a starting point to enhancing clinical options and
outcomes.
Barriers to Recommendation
Challenges and barriers exist in implementing
these recommendations. Challenges include the willingness of the clinical team to acknowledge and accept the literature enough to motivate change in their
practice. Furthermore, a comprehensive meta-analysis
of the literature needs to be synthesized to create a
more uniform understanding of and therefore trust in
the treatment of pregnant women with MDD. Barriers
that exist include limited knowledge regarding fetal
risk of untreated MDD in pregnancy, and the short and
long-term risks to the fetus of antidepressant exposure
during pregnancy. Confronting these issues remains
difficult because research involving pregnant women
in placebo-controlled trials is currently protected.
Conclusion and Opinion
To best determine the choice of treatment,
the nurse should use the current literature to guide
practice. This includes educating the patient on the
risks with a nomenclature that is not misleading. For
example, the research shows that using SSRIs during the late stages of pregnancy increases “relative
risk” of PPHN and is (statistically) “significant.” This
could imply a false risk versus the truth: that the risk
goes from 1 in 1000 births to 3 in 1000 births. Therefore, as additional information becomes available and
eventually resolves conflicting information regarding
the use of antidepressants, the better choices clinicians and patients will have. Thus, it is important that
researchers receive adequate funding so that clinicians
may better understand the risks and benefits of utilizing antidepressant medication as a treatment option
during pregnancy.
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